Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Yuanda Pharmaceutical regards interventional oncology produc...

Yuanda Pharmaceutical regards interventional oncology products as the company's strategic focus. LavATM was successfully listed in the US, providing a new direction for the expansion of the indications for Yigantaytrium [90Y] microspherical injection. The company will increase investment in research and development of anti-tumor nuclear drugs and promote collaboration between products under development and products currently on sale.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
See Original
Report
730 Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    3503Followers
    0Following
    8328Visitors
    Follow